Using the national new policy to open a new path of medication use, domestic unmarketed drugs in urgent clinical needs have been imported from Shanghai hospitals for the first time to "break the ice" and bring new hope to patients.

The list of pilot drug clinical trial institutions for the review and approval of clinical trials of optimized innovative drugs in Shanghai City was announced, and 14 were selected

Nearly 35 domestic iPSC companies have entered the market, and cytokines accelerate the development of universal cell therapies

The first round of drug price negotiations under the U.S. Inflation Reduction Act: 9 drugs have been reduced in price by more than 50%

iPSC treatment potential